Evidence map›Paper›PMID 34858829›Full record

ArticleFrontiers in oncology2021

Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction.

Yuan Tian, Jun Wang, Xueying Qiao, Jun Zhang, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01962246 (Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer), which is not on this map. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01962246 phase2 / phase3completednot on this map

Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer

TypeinterventionalSponsorHebei Medical UniversityRan2012 to 2021Enrolled169ConditionsGastroesophageal Junction AdenocarcinomaArmsOxaliplatin, Capecitabine, Oxaliplatin, Capecitabine, concurrent radiotherapy
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Guideline
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuan TianThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jun WangDepartment of Radiation, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xueying QiaoDepartment of Radiation, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jun ZhangDepartment of Radiation, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yong LiThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Liqiao FanThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhidong ZhangThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xuefeng ZhaoThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Bibo TanThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Dong WangThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Peigang YangThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Qun ZhaoThird Surgery Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReports have shown that neoadjuvant concurrent chemoradiotherapy (nCRT) increases the R0 resection rate for patients with Siewert type II or III adenocarcinoma of the gastroesophageal junction (AEG). However, the long-term efficacy of nCRT for AEG patients remains unclear. In this multicenter study, we investigated the long-term results of AEG patients treated with nCRT.

methodsA total of 149 patients with potentially resectable advanced AEG (T3/4, Nany, M0) were randomly divided into two groups: the nCRT-treated group (treated group) (

resultsIn the treated group, the overall therapeutic efficacy rate was 40.8%, and the pathological complete response (pCR) rate was 16.9%. The rates of patients who underwent R0 resection in the treated and control groups were 97.0% and 87.7%, respectively (

conclusionSurgery after nCRT improved the efficacy of treatment for AEG patients and thus provided a better prognosis. CLINICAL

trial registrationThe trial is registered with ClinicalTrials.gov (number NCT01962246).

Indexed as

adenocarcinoma of esophagogastric junctionadvancedneoadjuvant chemoradiotherapypotentially resectableSiewert II and IIItreatment

Identifiers

PMID34858829
PMCPMC8632141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.